Close
Achema middle east
swop processing & packaging

Endometrial Cancer Survival Is An Enhanced Possibility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

A Phase III trial found that pembrolizumab plus chemotherapy enhanced survival in endometrial cancer patients.

A Phase III clinical trial comparing pembrolizumab to chemotherapy (carboplatin and paclitaxel) enhanced progression-free survival (PFS) in patients with stage III-IV or recurrent endometrial cancer.

As per the interim analysis of the result, the treatment went on to show a statistically pivotal and clinically meaningful enhancement in the PFS, irrespective of the mismatch repair level. Status was explained by mismatch repair deficient-pMMD and mismatch repair efficient- pMMR.

Phase III trial related to pembrolizumab plus chemotherapy

NRG-GY018 happened to be a randomized, placebo-controlled, double-blind trial that included 819 women with stage III-IV or recurrent endometrial cancer. Pembrolizumab, carboplatin, and paclitaxel were given in combination to patients at random for six scheduled, 3-week cycles. Following this, there were up to fourteen 6-week cycles of pembrolizumab maintenance or placebo combination with carboplatin and paclitaxel, followed by placebo maintenance.

Treating Endometrial Carcinoma

The principal investigator of the trial, Dr. Ramez Eskander, explained why the positive findings from the analysis happen to be important. The patients suffering from the most common type of gynecologic cancer in the US, advanced or recurrent endometrial cancer, face a poor diagnosis and limited treatment options.

This research project for endometrial carcinoma was supported by NRG Oncology Operations funding from the National Cancer Institute, which is a part of the National Institute of Health. The study has been conducted by the NCI’s National Clinical Trials Network.

Latest stories

Related stories

Why Anti-Wrinkle Injections Are Gaining Popularity in Ireland

Over the past decade, Ireland has seen a significant...

Driving Excellence in Pharmaceutical Production with Advanced Pharmaceutical Cooling Systems

Introduction In pharmaceutical manufacturing, every degree matters. Process cooling is...

AstraZeneca and Daiichi Report Datroway Efficacy for TNBC

Datroway, a cancer drug developed by AstraZeneca and Daiichi...

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »